Aruna Kumar Subramanian, MD
Infectious Disease · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 10
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
10 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Subramanian’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
10 of 10 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence C56151 · Current
Licensed to practise in California · since 2013 · expires 2027-09-30 · University of Michigan Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$41,027
Medicare paid this office $41,027 for 134 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 66 | $15,367 | $106 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 55 | $8,828 | $155 |
| Critical care, first 30-74 minutes | 13 | $5,035 | $186 |
| Long return visit (40+ min) | 16 | $4,144 | $173 |
| Return visit (30+ min) | 11 | $1,357 | $123 |
Who their Medicare patients are
134 Original Medicare patients in 2024. Average age 67 · Under 65 31% · Women 40% · Also on Medicaid 43% · Health risk score 4.66. Sicker patients than 9 in 10 peers; the typical infectious disease clinician is at 3.
Conditions among them: High blood pressure 75% · Chronic kidney disease 61% · Heart failure 44% · Diabetes 43% · Coronary heart disease 40% · Atrial fibrillation 37% · COPD 36% · Depression 32% · Cancer 30% · Stroke 21% · Dementia 19%.
The office billed $199,020, Medicare allowed $51,748 and paid $41,027; for 324 services of 16 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 134 | 324 | 67 | 4.66 | $199,020 | $41,027 |
| 2023 | 118 | 308 | 67 | 4.11 | $143,822 | $33,185 |
| 2022 | 128 | 320 | 66 | 4.30 | $138,574 | $31,706 |
| 2021 | 139 | 370 | 68 | 3.73 | $176,646 | $37,761 |
| 2020 | 123 | 282 | 65 | 3.13 | $125,508 | $27,832 |
| 2019 | 147 | 457 | 66 | 3.82 | $154,175 | $49,682 |
| 2018 | 146 | 443 | 66 | 4.21 | $145,695 | $45,443 |
| 2017 | 106 | 229 | 66 | 3.70 | $63,768 | $21,364 |
| 2016 | 96 | 235 | 65 | 4.31 | $75,515 | $23,032 |
| 2015 | 111 | 335 | 66 | 3.25 | $111,028 | $33,843 |
| 2014 | 100 | 239 | 67 | 2.90 | $77,639 | $23,910 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 52 | $13,424 | $109 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 43 | $6,877 | $160 |
| Return visit (30+ min) | 22 | $3,827 | $89 |
| Long return visit (40+ min) | 19 | $3,657 | $131 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $2,113 | $70 |
2022: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 63 | $14,245 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $6,498 | $180 |
| Return visit (30+ min) | 26 | $4,133 | $84 |
| Long return visit (40+ min) | 11 | $1,578 | $131 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,109 | $65 |
2021: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $13,978 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $5,968 | $186 |
| Return visit (30+ min) | 25 | $3,784 | $92 |
| Long return visit (40+ min) | 18 | $3,117 | $142 |
| Long return visit (40+ min) | 11 | $2,652 | $147 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,328 | $66 |
| Telehealth originating site facility fee | 14 | $622 | $21 |
2020: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $9,334 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $6,104 | $191 |
| Return visit (30+ min) | 17 | $2,009 | $74 |
| Long return visit (40+ min) | 16 | $1,660 | $98 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,334 | $121 |
| New patient visit (45+ min) | 11 | $1,319 | $120 |
| Telehealth originating site facility fee | 14 | $467 | $21 |
2019: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 64 | $22,356 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 60 | $11,930 | $184 |
| Long return visit (40+ min) | 54 | $9,922 | $100 |
| Return visit (30+ min) | 14 | $1,148 | $72 |
2018: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 75 | $20,558 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 51 | $9,824 | $182 |
| Long return visit (40+ min) | 36 | $4,290 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $3,334 | $65 |
| New patient visit (60+ min) | 11 | $1,656 | $151 |
| Long return visit (40+ min) | 14 | $1,596 | $100 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,344 | $122 |
| Return visit (30+ min) | 11 | $918 | $71 |
2017: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $4,207 | $93 |
| Long return visit (40+ min) | 33 | $3,628 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,719 | $181 |
| Return visit (30+ min) | 31 | $2,719 | $66 |
| New patient visit (60+ min) | 15 | $2,255 | $150 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,587 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,296 | $65 |
| New patient visit (45+ min) | 11 | $1,271 | $116 |
| Short return visit (20+ min) | 12 | $685 | $46 |
2016: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $6,389 | $93 |
| Long return visit (40+ min) | 32 | $4,993 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,605 | $180 |
| New patient visit (60+ min) | 18 | $2,695 | $150 |
| Return visit (30+ min) | 29 | $2,381 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,736 | $64 |
2015: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $13,506 | $93 |
| Long return visit (40+ min) | 57 | $8,782 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $5,072 | $181 |
| New patient visit (60+ min) | 17 | $2,545 | $150 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,680 | $65 |
| Return visit (30+ min) | 12 | $1,050 | $70 |
2014: 6 services
| Long return visit (40+ min) | 48 | $6,710 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $5,268 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,777 | $180 |
| New patient visit (60+ min) | 22 | $3,291 | $150 |
| Return visit (30+ min) | 24 | $2,937 | $70 |
| New patient visit (30+ min) | 12 | $810 | $68 |
Medicaid work
$405 in 2024
Medicaid paid $405 for 20 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 20 | $405 |
| 2024 | 20 | 1 | 13 | $405 |
| 2021 | 80 | 1 | 13 | $4,102 |
| 2020 | 71 | 1 | 15 | $2,725 |
See the largest Medicaid services in earlier years
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 80 | $4,102 |
2020
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 71 | $2,725 |
Drugs they prescribed that Part D paid
$321,287
Pharmacies billed $321,287 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 124) in 2024. At or below the middle of the specialty; the typical infectious disease clinician is at 0%.
108 generic and 16 brand-name prescriptions · $321,287 in drug cost · 88 antibiotic prescriptions to 19 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ertapenem | 13 | $2,913 | $224 |
| Sulfamethoxazole-Trimethoprim | 17 | $503 | $30 |
| Amoxicillin-Clavulanate Potass | 13 | $410 | $32 |
Year by year
| 2024 | 124 | 27 | 0% (0) | 13% | $321,287 |
| 2023 | 106 | 18 | 0% (0) | 15% | $33,445 |
| 2022 | 116 | 25 | 0% (0) | 20% | $48,248 |
| 2021 | 219 | 36 | 0% (0) | 12% | $126,978 |
| 2020 | 218 | 40 | 0% (0) | 20% | $173,643 |
| 2019 | 245 | 46 | 0% (0) | 18% | $125,129 |
| 2018 | 123 | 30 | 0% (0) | None | $54,610 |
| 2017 | 149 | 33 | 0% (0) | 13% | $52,057 |
| 2016 | 104 | 28 | None | 24% | $67,679 |
| 2015 | 131 | 36 | None | 23% | $50,660 |
| 2014 | 132 | 28 | None | 27% | $121,977 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Vemlidy | 11 | $16,329 | $1,484 |
| Voriconazole | 11 | $2,726 | $248 |
| Sulfamethoxazole-Trimethoprim | 12 | $316 | $26 |
2022: 5 drugs
| Vemlidy | 13 | $18,226 | $1,402 |
| Valacyclovir | 14 | $1,545 | $110 |
| Famciclovir | 15 | $954 | $64 |
| Ciprofloxacin | 14 | $248 | $18 |
| Sulfamethoxazole-Trimethoprim | 15 | $193 | $13 |
2021: 8 drugs
| Ertapenem | 35 | $20,664 | $590 |
| Vemlidy | 13 | $16,878 | $1,298 |
| Valacyclovir | 33 | $3,041 | $92 |
| Colchicine | 16 | $2,937 | $184 |
| Aripiprazole | 18 | $2,025 | $113 |
| Famciclovir | 15 | $1,356 | $90 |
| Ciprofloxacin | 12 | $167 | $14 |
| Isoniazid | 13 | $130 | $10 |
2020: 8 drugs
| Cresemba | 12 | $64,199 | $5,350 |
| Vancomycin | 20 | $7,019 | $351 |
| Valacyclovir | 25 | $1,417 | $57 |
| Moxifloxacin | 11 | $1,342 | $122 |
| Rifampin | 15 | $1,001 | $67 |
| Dextrose 5%-0.45% Nacl-Kcl | 14 | $454 | $32 |
| Aripiprazole | 14 | $410 | $29 |
| Doxycycline Monohydrate | 11 | $322 | $29 |
2019: 6 drugs
| Vancomycin | 44 | $17,528 | $398 |
| Meropenem | 18 | $4,643 | $258 |
| Ampicillin | 11 | $1,838 | $167 |
| Valacyclovir | 17 | $770 | $45 |
| Dextrose 5%-0.45% Nacl-Kcl | 23 | $554 | $24 |
| Isoniazid | 15 | $110 | $7 |
2018: 5 drugs
| Voriconazole | 12 | $13,694 | $1,141 |
| Vancomycin | 11 | $4,547 | $413 |
| Fluconazole | 12 | $1,651 | $138 |
| Rifampin | 11 | $665 | $60 |
| Isoniazid | 16 | $146 | $9 |
2017: 4 drugs
| Vancomycin | 15 | $14,336 | $956 |
| Fluconazole | 23 | $2,134 | $93 |
| Diphenoxylate-Atropine | 13 | $244 | $19 |
| Isoniazid | 15 | $64 | $4 |
2016: 1 drug
| Fluconazole | 20 | $919 | $46 |
2015: 3 drugs
| Voriconazole | 13 | $29,158 | $2,243 |
| Amoxicillin-Clavulanate Potass | 12 | $282 | $24 |
| Amoxicillin | 12 | $179 | $15 |
2014: 3 drugs
| Dificid | 12 | $105,503 | $8,792 |
| Rifampin | 22 | $2,549 | $116 |
| Isoniazid | 21 | $148 | $7 |
Money from drug and device companies
$3,500 in 2023
| 2023 | 1 | 1 | $3,500 | $3,500 |
| 2022 | 1 | 1 | $1,260 | $1,260 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pfizer | None | $3,500 | 1 payment
|
See the published payment
| Pfizer | Honoraria · 2023-08-03 | None | $3,500 |
See earlier years (2022)
2022: $1,260
| Gilead Sciences | None | $1,260 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Gilead Sciences, Inc. · The Simple Study in Coronavirus, Severe Subjects · 2020 | Their institution | $562,271 |
| Regeneron Pharmaceuticals, Inc. · A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) Sars-Cov-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With Covid-19 · 2021 | Their institution | $269,447 |
| Gilead Sciences, Inc. · The Simple Study - Subjects With Mild To Moderate Coronavirus Infection · 2020 | Their institution | $194,775 |
| ModernaTX, Inc. · A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study To Evaluate the Efficacy, Safety, and Immunogenicity of Mrna-1647 Cytomegalovirus (Cmv) Vaccine in Healthy Participants 16 To 40 Years of Age · 2024 | Their institution | $105,701 |
| ModernaTX, Inc. · A Study To Evaluate the Efficacy, Safety, and Immunogenicity of Mrna-1647 Cytomegalovirus (Cmv) Vaccine in Healthy Participants 16 To 40 Years of Age · 2025 | Their institution | $82,048 |
| Regeneron Pharmaceuticals, Inc. · A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) Sars-Cov-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With Covid-19 · 2020 | Their institution | $77,457 |
| Regeneron Pharmaceuticals, Inc. · A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) Sars-Cov-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With Covid-19 · 2023 | Their institution | $77,325 |
| ModernaTX, Inc. · A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study To Evaluate the Efficacy, Safety, and Immunogenicity of Mrna-1647 Cytomegalovirus (Cmv) Vaccine in Healthy Participants 16 To 40 Years of Age · 2023 | Their institution | $61,989 |
| Gilead Sciences, Inc. · A Phase 1b/2a Study in A Phase 1b/2a Study in Participants With Early Stage Covid-19 To Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered By Inhalation · 2020 | Their institution | $26,840 |
| Gilead Sciences, Inc. · A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Covid-19 · 2021 | Their institution | $17,240 |
| Novartis Pharmaceuticals Corporation · Research Publication/ Writing Support · 2025 | This clinician | $7,228 |
| Gilead Sciences, Inc. · The Simple Study in Coronavirus, Severe Subjects · 2021 | Their institution | $5,800 |
| Gilead Sciences, Inc. · A Phase 1b/2a Study in A Phase 1b/2a Study in Participants With Early Stage Covid-19 To Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered By Inhalation · 2021 | Their institution | $646 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1356371082
- Licence
- CA C56151California C56151: Current · expires 2027-09-30
- Trained
- University of Michigan Medical School, 1994
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- MD 204701200
- Taxonomy
- Federal specialty code 207RI0200X (207RI0200X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-07-05
- NPI last updated
- 2024-04-17
- NPI record certified
- 2024-04-17
This is when the NPI record was last certified, not a medical board exam.